BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412-9. [PMID: 12591062 DOI: 10.1111/j.1572-0241.2003.07234.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 157] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Mahmood Atiyea Q, wadullah younus R, S .Abdulkareem H, Mahdi Hamad A. Efficacy of zinc oxide nanoparticles and Bifidobacterium bifidum Extraction on anaerobic bacteria isolated from patients with diarrhea. RB 2022;7:1-6. [DOI: 10.21931/rb/2022.07.04.57] [Reference Citation Analysis]
2 Kindt S, Louis H, De Schepper H, Arts J, Caenepeel P, De Looze D, Gerkens A, Holvoet T, Latour P, Mahler T, Mokaddem F, Nullens S, Piessevaux H, Poortmans P, Rasschaert G, Surmont M, Vafa H, Van Malderen K, Vanuytsel T, Wuestenberghs F, Tack J. Belgian consensus on irritable bowel syndrome. AGEB 2022;85:360-382. [DOI: 10.51821/85.2.10100] [Reference Citation Analysis]
3 Gu Y, Li L, Yang M, Liu T, Song X, Qin X, Xu X, Liu J, Wang B, Cao H. Bile acid-gut microbiota crosstalk in irritable bowel syndrome. Crit Rev Microbiol 2022;:1-20. [PMID: 35389754 DOI: 10.1080/1040841X.2022.2058353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Mamieva Z, Poluektova E, Svistushkin V, Sobolev V, Shifrin O, Guarner F, Ivashkin V. Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations? World J Gastroenterol 2022; 28(12): 1204-1219 [DOI: 10.3748/wjg.v28.i12.1204] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
5 Poon D, Law GR, Major G, Andreyev HJN. A systematic review and meta-analysis on the prevalence of non-malignant, organic gastrointestinal disorders misdiagnosed as irritable bowel syndrome. Sci Rep 2022;12:1949. [PMID: 35121775 DOI: 10.1038/s41598-022-05933-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Lee J, Paik CN, Kim DB, Lee JM, Kim YJ, Choi SK, Cho YJ. Role of Glucose Breath Test for Small Intestinal Bacterial Overgrowth in Children and Adolescents With Functional Abdominal Pain Disorders in Korea. J Neurogastroenterol Motil 2022;28:78-85. [PMID: 34980690 DOI: 10.5056/jnm20231] [Reference Citation Analysis]
7 Kim Y, Jo IH, Paik CN, Lee JM. Efficacies of prokinetics and rifaximin on the positivity to glucose breath test in patients with functional dyspepsia: randomized trial. Rev Esp Enferm Dig 2022. [DOI: 10.17235/reed.2022.8735/2022] [Reference Citation Analysis]
8 Wollny T, Daniluk T, Piktel E, Wnorowska U, Bukłaha A, Głuszek K, Durnaś B, Bucki R. Targeting the Gut Microbiota to Relieve the Symptoms of Irritable Bowel Syndrome. Pathogens 2021;10:1545. [PMID: 34959500 DOI: 10.3390/pathogens10121545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Okawa Y. Development of colonic transit time and ultrasound imaging tools as objective indicators for assessing abnormal defecation associated with food intake: a narrative review based on previous scientific knowledge. Biopsychosoc Med 2021;15:20. [PMID: 34742336 DOI: 10.1186/s13030-021-00222-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Benjak Horvat I, Gobin I, Kresović A, Hauser G. How can probiotic improve irritable bowel syndrome symptoms? World J Gastrointest Surg 2021; 13(9): 923-940 [PMID: 34621470 DOI: 10.4240/wjgs.v13.i9.923] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Razmjoo S, Bagheri A, Shahbazian H, Hosseini SM, Ebrahimian-Tabrizi F. Role of non-absorbable oral antibiotics in bowel preparation for intracavitary brachytherapy: effects of rifaximin on rectal dosimetric parameters during vaginal cuff brachytherapy. J Contemp Brachytherapy 2021;13:426-32. [PMID: 34484357 DOI: 10.5114/jcb.2021.108597] [Reference Citation Analysis]
12 Kessoku T, Kobayashi T, Tanaka K, Yamamoto A, Takahashi K, Iwaki M, Ozaki A, Kasai Y, Nogami A, Honda Y, Ogawa Y, Kato S, Imajo K, Higurashi T, Hosono K, Yoneda M, Usuda H, Wada K, Saito S, Nakajima A. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. Int J Mol Sci 2021;22:8161. [PMID: 34360923 DOI: 10.3390/ijms22158161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
13 Gandhi A, Shah A, Jones MP, Koloski N, Talley NJ, Morrison M, Holtmann G. Methane positive small intestinal bacterial overgrowth in inflammatory bowel disease and irritable bowel syndrome: A systematic review and meta-analysis. Gut Microbes 2021;13:1933313. [PMID: 34190027 DOI: 10.1080/19490976.2021.1933313] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
14 van Kessel L, Teunissen D, Lagro-Janssen T. Sex-Gender Differences in the Effectiveness of Treatment of Irritable Bowel Syndrome: A Systematic Review. Int J Gen Med 2021;14:867-84. [PMID: 33758534 DOI: 10.2147/IJGM.S291964] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Schindler V, Huellner M, Murray F, Schnurre L, Becker AS, Bordier V, Pohl D. Nutrient Challenge Testing Is Not Equivalent to Scintigraphy-Lactulose Hydrogen Breath Testing in Diagnosing Small Intestinal Bacterial Overgrowth. J Neurogastroenterol Motil 2020;26:514-20. [PMID: 32989187 DOI: 10.5056/jnm19162] [Reference Citation Analysis]
16 Li YJ, Li J, Dai C. The Role of Intestinal Microbiota and Mast Cell in a Rat Model of Visceral Hypersensitivity. J Neurogastroenterol Motil 2020;26:529-38. [PMID: 32989188 DOI: 10.5056/jnm20004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
17 Black CJ, Ford AC. How effective are antibiotics for the treatment of irritable bowel syndrome? Expert Opin Pharmacother 2020;21:2195-7. [PMID: 32835541 DOI: 10.1080/14656566.2020.1808623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Zhuang X, Tian Z, Luo M, Xiong L. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol 2020;20:187. [PMID: 32532214 DOI: 10.1186/s12876-020-01336-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Santos ANDR, Soares ACF, Oliveira RP, Morais MB. THE IMPACT OF SMALL INTESTINAL BACTERIAL OVERGROWTH ON THE GROWTH OF CHILDREN AND ADOLESCENTS. Rev Paul Pediatr 2020;38:e2018164. [PMID: 31939507 DOI: 10.1590/1984-0462/2020/38/2018164] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Andrews CN, Sidani S, Marshall JK. Clinical Management of the Microbiome in Irritable Bowel Syndrome. J Can Assoc Gastroenterol 2021;4:36-43. [PMID: 33644675 DOI: 10.1093/jcag/gwz037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
21 Chojnacki C, Konrad P, Błońska A, Chojnacki J, Mędrek-Socha M. Usefulness of the hydrogen breath test in patients with functional dyspepsia. Prz Gastroenterol 2020;15:338-42. [PMID: 33777274 DOI: 10.5114/pg.2020.92690] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Morales W, Rezaie A, Barlow G, Pimentel M. Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels. Dig Dis Sci 2019;64:3115-21. [PMID: 31152332 DOI: 10.1007/s10620-019-05684-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
23 Coelho LK, Carvalho NS, Navarro-Rodriguez T, Marson FAL, Carvalho PJPC. Lactulose Breath Testing Can Be a Positive Predictor Before Weight Gain in Participants with Obesity Submitted to Roux-en-Y Gastric Bypass. Obes Surg 2019;29:3457-64. [PMID: 31187458 DOI: 10.1007/s11695-019-04006-z] [Reference Citation Analysis]
24 Bin Waqar SH, Rehan A. Methane and Constipation-predominant Irritable Bowel Syndrome: Entwining Pillars of Emerging Neurogastroenterology. Cureus 2019;11:e4764. [PMID: 31363445 DOI: 10.7759/cureus.4764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Kvit KB, Kharchenko NV, Kharchenko VV, Chornenka OI, Chornovus RI, Dorofeeva US, Draganchuk OB, Slaba OM. THE ROLE OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN THE PATHOGENESIS OF HYPERLIPIDEMIA. Wiad Lek 2019;72:645-9. [DOI: 10.36740/wlek201904127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 Ghosh G, Jesudian AB. Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis. J Clin Exp Hepatol 2019;9:257-67. [PMID: 31024208 DOI: 10.1016/j.jceh.2018.08.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
27 Chang C. Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin. Clin Exp Gastroenterol 2018;11:335-45. [PMID: 30288076 DOI: 10.2147/CEG.S167031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
28 Daghaghzadeh H, Memar A, Mohamadi Y, Rezakhani N, Safazadeh P, Aghaha S, Adibi P. Therapeutic Effects of Low-dose Bismuth Subcitrate on Symptoms and Health-related Quality of Life in Adult Patients with Irritable Bowel Syndrome: A Clinical Trial. J Res Pharm Pract 2018;7:13-21. [PMID: 29755994 DOI: 10.4103/jrpp.JRPP_17_56] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Song KH, Jung HK, Kim HJ, Koo HS, Kwon YH, Shin HD, Lim HC, Shin JE, Kim SE, Cho DH, Kim JH, Kim HJ; Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. J Neurogastroenterol Motil. 2018;24:197-215. [PMID: 29605976 DOI: 10.5056/jnm17145] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
30 Rodiño-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-García R, Santos J. A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Adv Ther 2018;35:289-310. [PMID: 29498019 DOI: 10.1007/s12325-018-0673-5] [Cited by in Crossref: 106] [Cited by in F6Publishing: 117] [Article Influence: 21.2] [Reference Citation Analysis]
31 Stern EK, Brenner DM. Gut Microbiota-Based Therapies for Irritable Bowel Syndrome. Clin Transl Gastroenterol. 2018;9:e134. [PMID: 29446765 DOI: 10.1038/ctg.2018.2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
32 Xiong L, Wang Y, Gong X, Chen M. Prevalence of lactose intolerance in patients with diarrhea-predominant irritable bowel syndrome: data from a tertiary center in southern China. J Health Popul Nutr 2017;36:38. [PMID: 29157302 DOI: 10.1186/s41043-017-0113-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
33 Harris LA, Baffy N. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome. Postgrad Med 2017;129:872-88. [PMID: 28936910 DOI: 10.1080/00325481.2017.1383819] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
34 Ghoshal UC, Shukla R, Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut Liver. 2017;11:196-208. [PMID: 28274108 DOI: 10.5009/gnl16126] [Cited by in Crossref: 91] [Cited by in F6Publishing: 95] [Article Influence: 15.2] [Reference Citation Analysis]
35 Cash BD, Pimentel M, Rao SSC, Weinstock L, Chang L, Heimanson Z, Lembo A. Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. Therap Adv Gastroenterol 2017;10:689-99. [PMID: 28932270 DOI: 10.1177/1756283X17726087] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
36 Gupta K, Ghuman HS, Handa SV. Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile. Clin Med Insights Gastroenterol 2017;10:1179552217728905. [PMID: 28894393 DOI: 10.1177/1179552217728905] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
37 Melchior C, Gourcerol G, Bridoux V, Ducrotté P, Quinton JF, Leroi AM. Efficacy of antibiotherapy for treating flatus incontinence associated with small intestinal bacterial overgrowth: A pilot randomized trial. PLoS One 2017;12:e0180835. [PMID: 28763464 DOI: 10.1371/journal.pone.0180835] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
38 Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S, Pimentel M. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol 2017;112:775-84. [PMID: 28323273 DOI: 10.1038/ajg.2017.46] [Cited by in Crossref: 395] [Cited by in F6Publishing: 388] [Article Influence: 65.8] [Reference Citation Analysis]
39 Mearin F, Ciriza C, Mínguez M, Rey E, Mascort JJ, Peña E, Cañones P, Júdez J; en nombre de la SEPD, la semFYC, la SEMERGEN y la SEMG. [Irritable bowel syndrome with constipation and functional constipation in adults: Treatment (Part 2 of 2)]. Aten Primaria 2017;49:177-94. [PMID: 28238460 DOI: 10.1016/j.aprim.2017.01.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
40 Lee HJ, Choi JK, Ryu HS, Choi CH, Kang EH, Park KS, Min YW, Hong KS. Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders. J Neurogastroenterol Motil 2017;23:9-19. [PMID: 28049862 DOI: 10.5056/jnm16124] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
41 Kim JH, Lin E, Pimentel M. Biomarkers of Irritable Bowel Syndrome. J Neurogastroenterol Motil 2017;23:20-6. [PMID: 27817184 DOI: 10.5056/jnm16135] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
42 Pimentel M, Cash BD, Lembo A, Wolf RA, Israel RJ, Schoenfeld P. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. Dig Dis Sci 2017;62:2455-63. [PMID: 28589238 DOI: 10.1007/s10620-017-4598-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
43 Harrison E, Murray C, Lal S. Small and Large Intestinal Involvement and Nutritional Issues. Scleroderma 2017. [DOI: 10.1007/978-3-319-31407-5_31] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
44 Yazdani M, Aramesh A, Rafiei R, Daghaghzadeh H, Adibi P. The comparison of treatments with and without azithromycin in irritable bowel syndrome with diarrhea-predominant in gastrointestinal Clinic of Al-Zahra Hospital, Isfahan, Iran. Adv Biomed Res 2016;5:188. [PMID: 28028528 DOI: 10.4103/2277-9175.192737] [Reference Citation Analysis]
45 Rezaie A, Pimentel M, Rao SS. How to Test and Treat Small Intestinal Bacterial Overgrowth: An Evidence-Based Approach. Curr Gastroenterol Rep. 2016;18:8. [PMID: 26780631 DOI: 10.1007/s11894-015-0482-9] [Cited by in Crossref: 86] [Cited by in F6Publishing: 72] [Article Influence: 12.3] [Reference Citation Analysis]
46 Alavinejad P, Hashemi SJ, Hajiani E, Roomi A, Shahriari A, Karimi Moghaddam E. Low Dose Mesalazine Plus Bismuth Regimen and Symptoms of Irritable Bowel Syndrome in Patients with Bloating: A Quasi-Experimental Study. Jundishapur J Chronic Dis Care 2016;5. [DOI: 10.17795/jjcdc-35043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
47 Shayto RH, Abou Mrad R, Sharara AI. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol 2016; 22(29): 6638-6651 [PMID: 27547007 DOI: 10.3748/wjg.v22.i29.6638] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
48 Wadhwa A, Camilleri M, Grover M. New and Investigational Agents for Irritable Bowel Syndrome. Curr Gastroenterol Rep. 2015;17:46. [PMID: 26446557 DOI: 10.1007/s11894-015-0473-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
49 Lee SH, Kim KN, Kim KM, Joo NS. Irritable Bowel Syndrome May Be Associated with Elevated Alanine Aminotransferase and Metabolic Syndrome. Yonsei Med J 2016;57:146-52. [PMID: 26632395 DOI: 10.3349/ymj.2016.57.1.146] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
50 Vieira AT, Fukumori C, Ferreira CM. New insights into therapeutic strategies for gut microbiota modulation in inflammatory diseases. Clin Transl Immunology 2016;5:e87. [PMID: 27757227 DOI: 10.1038/cti.2016.38] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 9.3] [Reference Citation Analysis]
51 Chu H, Fox M, Zheng X, Deng Y, Long Y, Huang Z, Du L, Xu F, Dai N. Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome: Clinical Characteristics, Psychological Factors, and Peripheral Cytokines. Gastroenterol Res Pract. 2016;2016:3230859. [PMID: 27379166 DOI: 10.1155/2016/3230859] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
52 Newberry C, Tierney A, Pickett-Blakely O. Lactulose Hydrogen Breath Test Result Is Associated with Age and Gender. Biomed Res Int 2016;2016:1064029. [PMID: 27073800 DOI: 10.1155/2016/1064029] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
53 Thompson JR. Is irritable bowel syndrome an infectious disease? World J Gastroenterol 2016; 22(4): 1331-1334 [PMID: 26819502 DOI: 10.3748/wjg.v22.i4.1331] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
54 Bennet SM, Ohman L, Simren M. Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver. 2015;9:318-331. [PMID: 25918261 DOI: 10.5009/gnl14344] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 12.6] [Reference Citation Analysis]
55 Ringel-Kulka T, Choi CH, Temas D, Kim A, Maier DM, Scott K, Galanko JA, Ringel Y. Altered Colonic Bacterial Fermentation as a Potential Pathophysiological Factor in Irritable Bowel Syndrome. Am J Gastroenterol 2015;110:1339-46. [PMID: 26303129 DOI: 10.1038/ajg.2015.220] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 9.6] [Reference Citation Analysis]
56 Iorio N, Malik Z, Schey R. Profile of rifaximin and its potential in the treatment of irritable bowel syndrome. Clin Exp Gastroenterol 2015;8:159-67. [PMID: 26089696 DOI: 10.2147/CEG.S67231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
57 Theodorou V, Ait Belgnaoui A, Agostini S, Eutamene H. Effect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome. Gut Microbes. 2014;5:430-436. [PMID: 25184834 DOI: 10.4161/gmic.29796] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
58 Pimentel M, Morales W, Pokkunuri V, Brikos C, Kim SM, Kim SE, Triantafyllou K, Weitsman S, Marsh Z, Marsh E, Chua KS, Srinivasan S, Barlow GM, Chang C. Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model. Dig Dis Sci 2015;60:1195-205. [PMID: 25424202 DOI: 10.1007/s10620-014-3435-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
59 Rana SV, Malik A. Breath tests and irritable bowel syndrome. World J Gastroenterol. 2014;20:7587-7601. [PMID: 24976698 DOI: 10.3748/wjg.v20.i24] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Dlugosz A, Winckler B, Lundin E, Zakikhany K, Sandström G, Ye W, Engstrand L, Lindberg G. No difference in small bowel microbiota between patients with irritable bowel syndrome and healthy controls. Sci Rep. 2015;5:8508. [PMID: 25687743 DOI: 10.1038/srep08508] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 6.9] [Reference Citation Analysis]
61 Siniewicz-Luzeńczyk K, Bik-Gawin A, Zeman K, Bąk-Romaniszyn L. Small intestinal bacterial overgrowth syndrome in children. Prz Gastroenterol 2015;10:28-32. [PMID: 25960812 DOI: 10.5114/pg.2014.47494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
62 Savarino E, Savarino V, Fox M, Di Leo G, Furnari M, Marabotto E, Gemignani L, Bruzzone L, Moscatelli A, De Cassan C. Measurement of oro-caecal transit time by magnetic resonance imaging. Eur Radiol. 2015;25:1579-1587. [PMID: 25576231 DOI: 10.1007/s00330-014-3575-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
63 Gaci N, Borrel G, Tottey W, O’Toole PW, Brugère JF. Archaea and the human gut: New beginning of an old story. World J Gastroenterol 2014; 20(43): 16062-16078 [PMID: 25473158 DOI: 10.3748/wjg.v20.i43.16062] [Cited by in CrossRef: 223] [Cited by in F6Publishing: 226] [Article Influence: 24.8] [Reference Citation Analysis]
64 Iovino P, Bucci C, Tremolaterra F, Santonicola A, Chiarioni G. Bloating and functional gastro-intestinal disorders: Where are we and where are we going? World J Gastroenterol 2014; 20(39): 14407-14419 [PMID: 25339827 DOI: 10.3748/wjg.v20.i39.14407] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
65 Muller PA, Koscsó B, Rajani GM, Stevanovic K, Berres ML, Hashimoto D, Mortha A, Leboeuf M, Li XM, Mucida D, Stanley ER, Dahan S, Margolis KG, Gershon MD, Merad M, Bogunovic M. Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility. Cell 2014;158:300-13. [PMID: 25036630 DOI: 10.1016/j.cell.2014.04.050] [Cited by in Crossref: 363] [Cited by in F6Publishing: 377] [Article Influence: 40.3] [Reference Citation Analysis]
66 Koido S, Ohkusa T, Kan S, Takakura K, Saito K, Komita H, Ito Z, Kobayashi H, Takami S, Uchiyama K, Arakawa H, Ito M, Okamoto M, Kajihara M, Homma S, Tajiri H. Production of corticotropin-releasing factor and urocortin from human monocyte-derived dendritic cells is stimulated by commensal bacteria in intestine. World J Gastroenterol 2014; 20(39): 14420-14429 [PMID: 25339828 DOI: 10.3748/wjg.v20.i39.14420] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
67 Boltin D, Perets TT, Shporn E, Aizic S, Levy S, Niv Y, Dickman R. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome. Ann Clin Microbiol Antimicrob. 2014;13:49. [PMID: 25319626 DOI: 10.1186/s12941-014-0049-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
68 Soares RL. Irritable bowel syndrome: A clinical review. World J Gastroenterol 2014; 20(34): 12144-12160 [PMID: 25232249 DOI: 10.3748/wjg.v20.i34.12144] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 118] [Article Influence: 11.8] [Reference Citation Analysis]
69 Lee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol 2014; 20(27): 8886-8897 [PMID: 25083061 DOI: 10.3748/wjg.v20.i27.8886] [Cited by in F6Publishing: 41] [Reference Citation Analysis]
70 Lazaraki G, Chatzimavroudis G, Katsinelos P. Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol 2014; 20(27): 8867-8885 [PMID: 25083060 DOI: 10.3748/wjg.v20.i27.8867] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
71 Taverniti V, Guglielmetti S. Methodological issues in the study of intestinal microbiota in irritable bowel syndrome. World J Gastroenterol 2014; 20(27): 8821-8836 [PMID: 25083056 DOI: 10.3748/wjg.v20.i27.8821] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
72 Rana SV, Malik A. Breath tests and irritable bowel syndrome. World J Gastroenterol 2014; 20(24): 7587-7601 [PMID: 24976698 DOI: 10.3748/wjg.v20.i24.7587] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
73 Saha L. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol 2014; 20(22): 6759-6773 [PMID: 24944467 DOI: 10.3748/wjg.v20.i22.6759] [Cited by in CrossRef: 189] [Cited by in F6Publishing: 199] [Article Influence: 21.0] [Reference Citation Analysis]
74 Chedid V, Dhalla S, Clarke JO, Roland BC, Dunbar KB, Koh J, Justino E, Tomakin E, Mullin GE. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med 2014;3:16-24. [PMID: 24891990 DOI: 10.7453/gahmj.2014.019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
75 Pimentel M, Mathur R, Chang C. Gas and the microbiome. Curr Gastroenterol Rep. 2013;15:356. [PMID: 24150797 DOI: 10.1007/s11894-013-0356-y] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 6.9] [Reference Citation Analysis]
76 Vanuytsel T, Tack JF, Boeckxstaens GE. Treatment of abdominal pain in irritable bowel syndrome. J Gastroenterol. 2014;49:1193-1205. [PMID: 24845149 DOI: 10.1007/s00535-014-0966-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
77 Bye W, Ishaq N, Bolin TD, Duncombe VM, Riordan SM. Overgrowth of the indigenous gut microbiome and irritable bowel syndrome. World J Gastroenterol 2014; 20(10): 2449-2455 [PMID: 24627582 DOI: 10.3748/wjg.v20.i10.2449] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
78 Lee YJ, Park KS. Irritable bowel syndrome: Emerging paradigm in pathophysiology. World J Gastroenterol 2014; 20(10): 2456-2469 [PMID: 24627583 DOI: 10.3748/wjg.v20.i10.2456] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 97] [Article Influence: 10.3] [Reference Citation Analysis]
79 Hong SN, Rhee PL. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastroenterol 2014; 20(10): 2470-2481 [PMID: 24627584 DOI: 10.3748/wjg.v20.i10.2470] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 55] [Article Influence: 5.8] [Reference Citation Analysis]
80 DuPont AW, Jiang ZD, Harold SA, Snyder N, Galler GW, Garcia-Torres F, DuPont HL. Motility abnormalities in irritable bowel syndrome. Digestion 2014;89:119-23. [PMID: 24503633 DOI: 10.1159/000356314] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
81 Triantafyllou K, Chang C, Pimentel M. Methanogens, methane and gastrointestinal motility. J Neurogastroenterol Motil 2014;20:31-40. [PMID: 24466443 DOI: 10.5056/jnm.2014.20.1.31] [Cited by in Crossref: 146] [Cited by in F6Publishing: 151] [Article Influence: 14.6] [Reference Citation Analysis]
82 Imajo K, Yoneda M, Ogawa Y, Wada K, Nakajima A. Microbiota and nonalcoholic steatohepatitis. Semin Immunopathol. 2014;36:115-132. [PMID: 24337650 DOI: 10.1007/s00281-013-0404-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
83 Thompson A, Meah D, Ahmed N, Conniff-Jenkins R, Chileshe E, Phillips CO, Claypole TC, Forman DW, Row PE. Comparison of the antibacterial activity of essential oils and extracts of medicinal and culinary herbs to investigate potential new treatments for irritable bowel syndrome. BMC Complement Altern Med 2013;13:338. [PMID: 24283351 DOI: 10.1186/1472-6882-13-338] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
84 Choi CH. Are bloating and abdominal distention attributed to gas production and visceral sensitivity in irritable bowel syndrome? (Am j gastroenterol 2013;108:1516-1525). J Neurogastroenterol Motil 2013;19:544-6. [PMID: 24199019 DOI: 10.5056/jnm.2013.19.4.544] [Reference Citation Analysis]
85 Ringel Y, Maharshak N. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2013;305:G529-41. [PMID: 23886861 DOI: 10.1152/ajpgi.00207.2012] [Cited by in Crossref: 77] [Cited by in F6Publishing: 79] [Article Influence: 7.7] [Reference Citation Analysis]
86 Seo AY, Kim N, Oh DH. Abdominal bloating: pathophysiology and treatment. J Neurogastroenterol Motil 2013;19:433-53. [PMID: 24199004 DOI: 10.5056/jnm.2013.19.4.433] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
87 Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2013;38:925-34. [PMID: 24004101 DOI: 10.1111/apt.12479] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 11.4] [Reference Citation Analysis]
88 Ohman L, Simrén M. Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr Gastroenterol Rep. 2013;15:323. [PMID: 23580243 DOI: 10.1007/s11894-013-0323-7] [Cited by in Crossref: 80] [Cited by in F6Publishing: 90] [Article Influence: 8.0] [Reference Citation Analysis]
89 Lee KN, Lee OY, Koh DH, Sohn W, Lee SP, Jun DW, Lee HL, Yoon BC, Choi HS, Hahm JS. Association between symptoms of irritable bowel syndrome and methane and hydrogen on lactulose breath test. J Korean Med Sci. 2013;28:901-907. [PMID: 23772156 DOI: 10.3346/jkms.2013.28.6.901] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
90 Choung RS, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Associations between medication use and functional gastrointestinal disorders: a population-based study. Neurogastroenterol Motil 2013;25:413-9, e298. [PMID: 23360217 DOI: 10.1111/nmo.12082] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
91 Saadi M, McCallum RW. Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use. Ther Adv Chronic Dis. 2013;4:71-75. [PMID: 23556126 DOI: 10.1177/2040622312472008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
92 Wang ZK, Yang YS. Upper gastrointestinal microbiota and digestive diseases. World J Gastroenterol 2013; 19(10): 1541-1550 [PMID: 23539678 DOI: 10.3748/wjg.v19.i10.1541] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 63] [Article Influence: 6.1] [Reference Citation Analysis]
93 Occhipinti K, Smith JW. Irritable bowel syndrome: a review and update. Clin Colon Rectal Surg. 2012;25:46-52. [PMID: 23449495 DOI: 10.1055/s-0032-1301759] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
94 Sachdev AH, Pimentel M. Antibiotics for irritable bowel syndrome: rationale and current evidence. Curr Gastroenterol Rep. 2012;14:439-445. [PMID: 22945316 DOI: 10.1007/s11894-012-0284-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
95 Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013;62:159-76. [PMID: 22730468 DOI: 10.1136/gutjnl-2012-302167] [Cited by in Crossref: 586] [Cited by in F6Publishing: 531] [Article Influence: 58.6] [Reference Citation Analysis]
96 Kim G, Deepinder F, Morales W, Hwang L, Weitsman S, Chang C, Gunsalus R, Pimentel M. Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. Dig Dis Sci 2012;57:3213-8. [PMID: 22573345 DOI: 10.1007/s10620-012-2197-1] [Cited by in Crossref: 105] [Cited by in F6Publishing: 103] [Article Influence: 9.5] [Reference Citation Analysis]
97 Engsbro AL, Stensvold CR, Nielsen HV, Bytzer P. Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome. Am J Trop Med Hyg 2012;87:1046-52. [PMID: 23091195 DOI: 10.4269/ajtmh.2012.11-0761] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
98 Chang HY, Kelly EC, Lembo AJ. Current gut-directed therapies for irritable bowel syndrome. Curr Treat Options Gastroenterol. 2006;9:314-323. [PMID: 16836950 DOI: 10.1007/s11938-006-0013-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
99 Chang MS, Green PH. A review of rifaximin and bacterial overgrowth in poorly responsive celiac disease. Therap Adv Gastroenterol 2012;5:31-6. [PMID: 22282706 DOI: 10.1177/1756283X11422264] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
100 Wells M, Roth L, McWilliam M, Thompson K, Chande N. A cross-sectional study of the association between overnight call and irritable bowel syndrome in medical students. Can J Gastroenterol 2012;26:281-4. [PMID: 22590702 DOI: 10.1155/2012/865915] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
101 Koo HL, Sabounchi S, Huang DB, DuPont HL. Rifaximin therapy of irritable bowel syndrome. Clin Med Insights Gastroenterol 2012;5:31-41. [PMID: 24833932 DOI: 10.4137/CGast.S7382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
102 Olden KW. Targeted therapies for diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol. 2012;5:69-100. [PMID: 22754282 DOI: 10.2147/CEG.S290] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
103 Olden KW. Targeted therapies for diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol. 2012;5:69-100. [PMID: 22754282 DOI: 10.2147/CEG.S29023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
104 Madrid AM, Landskron G, Klapp G, Reyes A, Pizarro C, Defilippi C. Lactulose hydrogen breath test and functional symptoms in pediatric patients. Dig Dis Sci 2012;57:1330-5. [PMID: 22297652 DOI: 10.1007/s10620-012-2032-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
105 Ghoshal UC, Shukla R, Ghoshal U, Gwee KA, Ng SC, Quigley EM. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam. 2012;2012:151085. [PMID: 22577594 DOI: 10.1155/2012/151085] [Cited by in Crossref: 94] [Cited by in F6Publishing: 108] [Article Influence: 8.5] [Reference Citation Analysis]
106 Yakoob J, Abbas Z, Khan R, Hamid S, Awan S, Jafri W. Small intestinal bacterial overgrowth and lactose intolerance contribute to irritable bowel syndrome symptomatology in Pakistan. Saudi J Gastroenterol 2011;17:371-5. [PMID: 22064333 DOI: 10.4103/1319-3767.87176] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
107 Lacy BE, Weiser K, De Lee R. The treatment of irritable bowel syndrome. Therap Adv Gastroenterol. 2009;2:221-238. [PMID: 21180545 DOI: 10.1177/1756283x09104794] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
108 Chang MS, Minaya MT, Cheng J, Connor BA, Lewis SK, Green PH. Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. Dig Dis Sci 2011;56:2939-46. [PMID: 21647654 DOI: 10.1007/s10620-011-1719-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
109 Hojo M, Ohkusa T, Tomeoku H, Koido S, Asaoka D, Nagahara A, Watanabe S. Corticotropin-releasing factor secretion from dendritic cells stimulated by commensal bacteria. World J Gastroenterol 2011; 17(35): 4017-4022 [PMID: 22046091 DOI: 10.3748/wjg.v17.i35.4017] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
110 Pimentel M, Lezcano S. Irritable Bowel Syndrome: Bacterial Overgrowth--What’s Known and What to Do. Curr Treat Options Gastroenterol. 2007;10:328-337. [PMID: 17761126 DOI: 10.1007/s11938-007-0076-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
111 Quigley EM. Do Patients with Functional Gastrointestinal Disorders have an Altered Gut Flora? Therap Adv Gastroenterol. 2009;2:23-30. [PMID: 21180551 DOI: 10.1177/1756283X09335636] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
112 Whorwell PJ. Do probiotics improve symptoms in patients with irritable bowel syndrome? Ther Adv Gastroenterol. 2009;2:S37-S44. [PMID: 21180553 DOI: 10.1177/1756283x09335637] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
113 Youn YH, Park JS, Jahng JH, Lim HC, Kim JH, Pimentel M, Park H, Lee SI. Relationships among the lactulose breath test, intestinal gas volume, and gastrointestinal symptoms in patients with irritable bowel syndrome. Dig Dis Sci 2011;56:2059-66. [PMID: 21240630 DOI: 10.1007/s10620-011-1569-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
114 Stanghellini V, Barbara G, Cremon C, Cogliandro R, Antonucci A, Gabusi V, Frisoni C, De Giorgio R, Grasso V, Serra M. Gut microbiota and related diseases: clinical features. Intern Emerg Med. 2010;5 Suppl 1:S57-S63. [PMID: 20865476 DOI: 10.1007/s11739-010-0451-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
115 Katiraei P, Bultron G. Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome. World J Gastroenterol 2011; 17(23): 2791-2800 [PMID: 21734786 DOI: 10.3748/wjg.v17.i23.2791] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
116 Kunkel D, Basseri RJ, Makhani MD, Chong K, Chang C, Pimentel M. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci 2011;56:1612-8. [PMID: 21286935 DOI: 10.1007/s10620-011-1590-5] [Cited by in Crossref: 120] [Cited by in F6Publishing: 103] [Article Influence: 10.0] [Reference Citation Analysis]
117 Shanab AA, Scully P, Crosbie O, Buckley M, O'Mahony L, Shanahan F, Gazareen S, Murphy E, Quigley EM. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011;56:1524-34. [PMID: 21046243 DOI: 10.1007/s10620-010-1447-3] [Cited by in Crossref: 133] [Cited by in F6Publishing: 137] [Article Influence: 11.1] [Reference Citation Analysis]
118 Quigley EM. Microflora modulation of motility. J Neurogastroenterol Motil. 2011;17:140-147. [PMID: 21602990 DOI: 10.5056/jnm.2011.17.2.140] [Cited by in Crossref: 81] [Cited by in F6Publishing: 85] [Article Influence: 6.8] [Reference Citation Analysis]
119 Jolley J. High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clin Exp Gastroenterol 2011;4:43-8. [PMID: 21694871 DOI: 10.2147/CEG.S18051] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
120 Madrid AM, Poniachik J, Quera R, Defilippi C. Small intestinal clustered contractions and bacterial overgrowth: a frequent finding in obese patients. Dig Dis Sci 2011;56:155-60. [PMID: 20431947 DOI: 10.1007/s10620-010-1239-9] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
121 Di Stefano M, Tana P, Mengoli C, Miceli E, Pagani E, Corazza GR. Colonic hypersensitivity is a major determinant of the efficacy of bloating treatment in constipation-predominant irritable bowel syndrome. Intern Emerg Med 2011;6:403-11. [PMID: 21161699 DOI: 10.1007/s11739-010-0496-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
122 Carroll IM, Chang YH, Park J, Sartor RB, Ringel Y. Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog. 2010;2:19. [PMID: 21143915 DOI: 10.1186/1757-4749-2-19] [Cited by in Crossref: 137] [Cited by in F6Publishing: 145] [Article Influence: 10.5] [Reference Citation Analysis]
123 Rodríguez-Fandiño O, Hernández-Ruiz J, Schmulson M. From cytokines to toll-like receptors and beyond - current knowledge and future research needs in irritable bowel syndrome. J Neurogastroenterol Motil 2010;16:363-73. [PMID: 21103418 DOI: 10.5056/jnm.2010.16.4.363] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
124 Jee SR, Morales W, Low K, Chang C, Zhu A, Pokkunuri V, Chatterjee S, Soffer E, Conklin JL, Pimentel M. ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. World J Gastroenterol 2010; 16(29): 3680-3686 [PMID: 20677340 DOI: 10.3748/wjg.v16.i29.3680] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
125 Sahakian AB, Jee SR, Pimentel M. Methane and the gastrointestinal tract. Dig Dis Sci 2010;55:2135-43. [PMID: 19830557 DOI: 10.1007/s10620-009-1012-0] [Cited by in Crossref: 151] [Cited by in F6Publishing: 145] [Article Influence: 11.6] [Reference Citation Analysis]
126 Bures J, Cyrany J, Kohoutova D, Förstl M, Rejchrt S, Kvetina J, Vorisek V, Kopacova M. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 2010; 16(24): 2978-2990 [PMID: 20572300 DOI: 10.3748/wjg.v16.i24.2978] [Cited by in CrossRef: 371] [Cited by in F6Publishing: 416] [Article Influence: 28.5] [Reference Citation Analysis]
127 Weinstock LB, Walters AS, Mullin GE, Duntley SP. Celiac disease is associated with restless legs syndrome. Dig Dis Sci 2010;55:1667-73. [PMID: 19731029 DOI: 10.1007/s10620-009-0943-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
128 Mathur R, Ko A, Hwang LJ, Low K, Azziz R, Pimentel M. Polycystic ovary syndrome is associated with an increased prevalence of irritable bowel syndrome. Dig Dis Sci 2010;55:1085-9. [PMID: 19697132 DOI: 10.1007/s10620-009-0890-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
129 Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Arch Med Sci. 2010;6:49-55. [PMID: 22371720 DOI: 10.5114/aoms.2010.13507] [Cited by in Crossref: 20] [Cited by in F6Publishing: 33] [Article Influence: 1.5] [Reference Citation Analysis]
130 Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163-73. [PMID: 20101257 DOI: 10.1038/nrgastro.2010.4] [Cited by in Crossref: 399] [Cited by in F6Publishing: 370] [Article Influence: 30.7] [Reference Citation Analysis]
131 Reddymasu SC, Sostarich S, McCallum RW. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? BMC Gastroenterol. 2010;10:23. [PMID: 20175924 DOI: 10.1186/1471-230x-10-23] [Cited by in Crossref: 52] [Cited by in F6Publishing: 60] [Article Influence: 4.0] [Reference Citation Analysis]
132 Codling C, O'Mahony L, Shanahan F, Quigley EM, Marchesi JR. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 2010;55:392-7. [PMID: 19693670 DOI: 10.1007/s10620-009-0934-x] [Cited by in Crossref: 185] [Cited by in F6Publishing: 180] [Article Influence: 14.2] [Reference Citation Analysis]
133 Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010;26:17-25. [PMID: 19881343 DOI: 10.1097/MOG.0b013e328333dc8d] [Cited by in Crossref: 116] [Cited by in F6Publishing: 117] [Article Influence: 8.9] [Reference Citation Analysis]
134 Collins BS, Lin HC. Chronic abdominal pain in children is associated with high prevalence of abnormal microbial fermentation. Dig Dis Sci 2010;55:124-30. [PMID: 19888655 DOI: 10.1007/s10620-009-1026-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
135 Fernández-Bañares F, Esteve M, Viver JM. Fructose-sorbitol malabsorption. Curr Gastroenterol Rep 2009;11:368-74. [PMID: 19765364 DOI: 10.1007/s11894-009-0056-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
136 Camilleri M, Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis 2009;41:854-62. [PMID: 19665953 DOI: 10.1016/j.dld.2009.07.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
137 Charlett A, Dobbs RJ, Dobbs SM, Weller C, Ibrahim MA, Dew T, Sherwood R, Oxlade NL, Plant JM, Bowthorpe J. Blood profile holds clues to role of infection in a premonitory state for idiopathic parkinsonism and of gastrointestinal infection in established disease. Gut Pathog. 2009;1:20. [PMID: 19941660 DOI: 10.1186/1757-4749-1-20] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
138 Park JH, Park DI, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Won KH, Park SM. The Relationship between Small-Intestinal Bacterial Overgrowth and Intestinal Permeability in Patients with Irritable Bowel Syndrome. Gut Liver 2009;3:174-9. [PMID: 20431742 DOI: 10.5009/gnl.2009.3.3.174] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
139 Kerckhoffs AP, Samsom M, van der Rest ME, de Vogel J, Knol J, Ben-Amor K, Akkermans LM. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15(23): 2887-2892 [PMID: 19533811 DOI: 10.3748/wjg.15.2887] [Cited by in CrossRef: 201] [Cited by in F6Publishing: 211] [Article Influence: 14.4] [Reference Citation Analysis]
140 Verdu EF, Armstrong D, Murray JA. Between celiac disease and irritable bowel syndrome: the "no man's land" of gluten sensitivity. Am J Gastroenterol 2009;104:1587-94. [PMID: 19455131 DOI: 10.1038/ajg.2009.188] [Cited by in Crossref: 217] [Cited by in F6Publishing: 216] [Article Influence: 15.5] [Reference Citation Analysis]
141 Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 2009;136:2015-31. [PMID: 19462507 DOI: 10.1053/j.gastro.2009.01.072] [Cited by in Crossref: 349] [Cited by in F6Publishing: 362] [Article Influence: 24.9] [Reference Citation Analysis]
142 Al-Khatib K, Lin HC. Immune activation and gut microbes in irritable bowel syndrome. Gut Liver. 2009;3:14-19. [PMID: 20479895 DOI: 10.5009/gnl.2009.3.1.14] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
143 Jonderko K, Gabriel-Jaśniok A, Szymszal M, Kasicka-Jonderko A, Błońska-Fajfrowska B. Unreliability of breath methane as a candidate indicator of functional bowel disorders. Gut Liver 2008;2:180-5. [PMID: 20485644 DOI: 10.5009/gnl.2008.2.3.180] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
144 Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol 2008;103:2972-6. [PMID: 19086951 DOI: 10.1111/j.1572-0241.2008.01992.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Camilleri M, Chang L. Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology 2008;135:1877-91. [PMID: 18848833 DOI: 10.1053/j.gastro.2008.09.005] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
146 Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol 2008;103:2972-6. [PMID: 19086951 DOI: 10.1111/j.1572-0241.2008.01992.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 4.7] [Reference Citation Analysis]
147 Barrett JS, Canale KE, Gearry RB, Irving PM, Gibson PR. Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J Gastroenterol 2008; 14(32): 5020-5024 [PMID: 18763284 DOI: 10.3748/wjg.14.5020] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 51] [Article Influence: 3.1] [Reference Citation Analysis]
148 Parkes GC, Brostoff J, Whelan K, Sanderson JD. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 2008;103:1557-67. [PMID: 18513268 DOI: 10.1111/j.1572-0241.2008.01869.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 118] [Article Influence: 7.5] [Reference Citation Analysis]
149 Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 2008;53:1443-54. [PMID: 17990113 DOI: 10.1007/s10620-007-0065-1] [Cited by in Crossref: 198] [Cited by in F6Publishing: 172] [Article Influence: 13.2] [Reference Citation Analysis]
150 Hammerle CW, Surawicz CM. Updates on treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14(17): 2639-2649 [PMID: 18461649 DOI: 10.3748/wjg.14.2639] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
151 Weinstock LB, Fern SE, Duntley SP. Restless legs syndrome in patients with irritable bowel syndrome: response to small intestinal bacterial overgrowth therapy. Dig Dis Sci 2008;53:1252-6. [PMID: 17934858 DOI: 10.1007/s10620-007-0021-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
152 Weinstock LB, Klutke CG, Lin HC. Small intestinal bacterial overgrowth in patients with interstitial cystitis and gastrointestinal symptoms. Dig Dis Sci 2008;53:1246-51. [PMID: 17932763 DOI: 10.1007/s10620-007-0022-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
153 Tuteja AK, Talley NJ, Joos SK, Tolman KG, Hickam DH. Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders. Am J Gastroenterol 2008;103:1241-8. [PMID: 18422817 DOI: 10.1111/j.1572-0241.2007.01755.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
154 Pimentel M, Chatterjee S, Chang C, Low K, Song Y, Liu C, Morales W, Ali L, Lezcano S, Conklin J, Finegold S. A new rat model links two contemporary theories in irritable bowel syndrome. Dig Dis Sci 2008;53:982-9. [PMID: 17934822 DOI: 10.1007/s10620-007-9977-z] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 4.1] [Reference Citation Analysis]
155 Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 2008;103:958-63. [PMID: 18371134 DOI: 10.1111/j.1572-0241.2008.01785.x] [Cited by in Crossref: 124] [Cited by in F6Publishing: 113] [Article Influence: 8.3] [Reference Citation Analysis]
156 Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008;53:169-74. [PMID: 17520365 DOI: 10.1007/s10620-007-9839-8] [Cited by in Crossref: 89] [Cited by in F6Publishing: 92] [Article Influence: 5.9] [Reference Citation Analysis]
157 Gupta D, Ghoshal UC, Misra A, Misra A, Choudhuri G, Singh K. Lactose intolerance in patients with irritable bowel syndrome from northern India: a case-control study. J Gastroenterol Hepatol 2007;22:2261-5. [PMID: 17559357 DOI: 10.1111/j.1440-1746.2007.04986.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
158 Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P; Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-98. [PMID: 17488783 DOI: 10.1136/gut.2007.119446] [Cited by in Crossref: 560] [Cited by in F6Publishing: 506] [Article Influence: 35.0] [Reference Citation Analysis]
159 Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P; Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-98. [PMID: 17488783 DOI: 10.1136/gut.2007.119446] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
160 Bradesi S, Mayer EA. Novel therapeutic approaches in IBS. Curr Opin Pharmacol 2007;7:598-604. [PMID: 18006379 DOI: 10.1016/j.coph.2007.09.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
161 Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007;56:802-8. [PMID: 17148502 DOI: 10.1136/gut.2006.108712] [Cited by in Crossref: 368] [Cited by in F6Publishing: 291] [Article Influence: 23.0] [Reference Citation Analysis]
162 Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol. 2007;42 Suppl 17:41-47. [PMID: 17238025 DOI: 10.1007/s00535-006-1925-8] [Cited by in Crossref: 126] [Cited by in F6Publishing: 118] [Article Influence: 7.9] [Reference Citation Analysis]
163 Chatterjee S, Park S, Low K, Kong Y, Pimentel M. The degree of breath methane production in IBS correlates with the severity of constipation. Am J Gastroenterol 2007;102:837-41. [PMID: 17397408 DOI: 10.1111/j.1572-0241.2007.01072.x] [Cited by in Crossref: 152] [Cited by in F6Publishing: 148] [Article Influence: 9.5] [Reference Citation Analysis]
164 Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007;19:166-72. [PMID: 17300285 DOI: 10.1111/j.1365-2982.2006.00879.x] [Cited by in Crossref: 95] [Cited by in F6Publishing: 78] [Article Influence: 5.9] [Reference Citation Analysis]
165 Quigley EM. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. J Dig Dis 2007;8:2-7. [PMID: 17261128 DOI: 10.1111/j.1443-9573.2007.00277.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 3.0] [Reference Citation Analysis]
166 Fan YJ, Chen SJ, Yu YC, Si JM, Liu B. A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial. J Zhejiang Univ Sci B. 2006;7:987-991. [PMID: 17111468 DOI: 10.1631/jzus.2006.B0987] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
167 Azpiroz F, Bouin M, Camilleri M, Mayer EA, Poitras P, Serra J, Spiller RC. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 2007;19:62-88. [PMID: 17280586 DOI: 10.1111/j.1365-2982.2006.00875.x] [Cited by in Crossref: 258] [Cited by in F6Publishing: 205] [Article Influence: 16.1] [Reference Citation Analysis]
168 Andresen V, Camilleri M. Irritable bowel syndrome: recent and novel therapeutic approaches. Drugs. 2006;66:1073-1088. [PMID: 16789793 DOI: 10.2165/00003495-200666080-00004] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 3.4] [Reference Citation Analysis]
169 Harris LA, Hansel S, DiBaise J, Crowell MD. Irritable bowel syndrome and chronic constipation: emerging drugs, devices, and surgical treatments. Curr Gastroenterol Rep 2006;8:282-90. [PMID: 16888869 DOI: 10.1007/s11894-006-0048-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
170 Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci 2006;51:1297-301. [PMID: 16832617 DOI: 10.1007/s10620-006-9104-6] [Cited by in Crossref: 111] [Cited by in F6Publishing: 94] [Article Influence: 6.5] [Reference Citation Analysis]
171 Park MI, Camilleri M. Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review. Neurogastroenterol Motil 2006;18:595-607. [PMID: 16918724 DOI: 10.1111/j.1365-2982.2005.00745.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 96] [Article Influence: 5.7] [Reference Citation Analysis]
172 Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective. Aliment Pharmacol Ther 2006;24:183-205. [PMID: 16842448 DOI: 10.1111/j.1365-2036.2006.02938.x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 104] [Article Influence: 6.5] [Reference Citation Analysis]
173 Heading R, Bardhan K, Hollerbach S, Lanas A, Fisher G. Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective. Aliment Pharmacol Ther 2006;24:207-36. [PMID: 16842449 DOI: 10.1111/j.1365-2036.2006.02937.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 1.2] [Reference Citation Analysis]
174 Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-90. [PMID: 16863564 DOI: 10.1111/j.1572-0241.2006.00734.x] [Cited by in Crossref: 562] [Cited by in F6Publishing: 563] [Article Influence: 33.1] [Reference Citation Analysis]
175 Posserud I, Ersryd A, Simrén M. Functional findings in irritable bowel syndrome. World J Gastroenterol 2006; 12(18): 2830-2838 [PMID: 16718806 DOI: 10.3748/wjg.v12.i18.2830] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 47] [Article Influence: 2.6] [Reference Citation Analysis]
176 Simrén M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut 2006;55:297-303. [PMID: 16474100 DOI: 10.1136/gut.2005.075127] [Cited by in Crossref: 297] [Cited by in F6Publishing: 256] [Article Influence: 17.5] [Reference Citation Analysis]
177 Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006;101:326-33. [PMID: 16454838 DOI: 10.1111/j.1572-0241.2006.00458.x] [Cited by in Crossref: 226] [Cited by in F6Publishing: 230] [Article Influence: 13.3] [Reference Citation Analysis]
178 Quigley EM. Germs, gas and the gut; the evolving role of the enteric flora in IBS. Am J Gastroenterol 2006;101:334-5. [PMID: 16454839 DOI: 10.1111/j.1572-0241.2006.00445.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
179 Quigley EM. Changing face of irritable bowel syndrome. World J Gastroenterol 2006; 12(1): 1-5 [PMID: 16440408 DOI: 10.3748/wjg.v12.i1.1] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 47] [Article Influence: 2.6] [Reference Citation Analysis]
180 Quigley EM. Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases? Chin J Dig Dis. 2005;6:122-132. [PMID: 16045602 DOI: 10.1111/j.1443-9573.2005.00202.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 2.4] [Reference Citation Analysis]
181 Van Citters GW, Lin HC. Management of small intestinal bacterial overgrowth. Curr Gastroenterol Rep. 2005;7:317-320. [PMID: 16042917 DOI: 10.1007/s11894-005-0025-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 0.9] [Reference Citation Analysis]
182 Lupascu A, Gabrielli M, Lauritano EC, Scarpellini E, Santoliquido A, Cammarota G, Flore R, Tondi P, Pola P, Gasbarrini G, Gasbarrini A. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005;22:1157-60. [PMID: 16305730 DOI: 10.1111/j.1365-2036.2005.02690.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 107] [Article Influence: 7.2] [Reference Citation Analysis]
183 Barbara G, Stanghellini V, Brandi G, Cremon C, Di Nardo G, De Giorgio R, Corinaldesi R. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 2005;100:2560-8. [PMID: 16279914 DOI: 10.1111/j.1572-0241.2005.00230.x] [Cited by in Crossref: 202] [Cited by in F6Publishing: 202] [Article Influence: 11.2] [Reference Citation Analysis]
184 Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005;17:687-96. [PMID: 16185307 DOI: 10.1111/j.1365-2982.2005.00695.x] [Cited by in Crossref: 277] [Cited by in F6Publishing: 277] [Article Influence: 15.4] [Reference Citation Analysis]
185 Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol 2005;100:1566-70. [PMID: 15984983 DOI: 10.1111/j.1572-0241.2005.40795.x] [Cited by in Crossref: 125] [Cited by in F6Publishing: 127] [Article Influence: 6.9] [Reference Citation Analysis]
186 Azpiroz F. Intestinal gas dynamics: mechanisms and clinical relevance. Gut 2005;54:893-5. [PMID: 15951528 DOI: 10.1136/gut.2004.048868] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
187 Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, Scarpellini E, Vincenti F, Cammarota G, Flore R, Pola P, Gasbarrini G, Gasbarrini A. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005;22:31-5. [PMID: 15963077 DOI: 10.1111/j.1365-2036.2005.02516.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 4.4] [Reference Citation Analysis]
188 Tillisch K, Chang L. Diagnosis and treatment of irritable bowel syndrome: State of the art. Curr Gastroenterol Rep 2005;7:249-56. [DOI: 10.1007/s11894-005-0016-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
189 Gibson PR, Shepherd SJ. Personal view: food for thought--western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis. Aliment Pharmacol Ther 2005;21:1399-409. [PMID: 15948806 DOI: 10.1111/j.1365-2036.2005.02506.x] [Cited by in Crossref: 229] [Cited by in F6Publishing: 197] [Article Influence: 12.7] [Reference Citation Analysis]
190 Nucera G, Gabrielli M, Lupascu A, Lauritano EC, Santoliquido A, Cremonini F, Cammarota G, Tondi P, Pola P, Gasbarrini G, Gasbarrini A. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005;21:1391-5. [PMID: 15932370 DOI: 10.1111/j.1365-2036.2005.02493.x] [Cited by in Crossref: 133] [Cited by in F6Publishing: 107] [Article Influence: 7.4] [Reference Citation Analysis]
191 Camilleri M. Mechanisms in IBS: something old, something new, something borrowed.. Neurogastroenterol Motil 2005;17:311-6. [PMID: 15916617 DOI: 10.1111/j.1365-2982.2004.00632.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
192 Reina J, Smith JW. Medical treatment of irritable bowel syndrome. Clin Colon Rectal Surg 2005;18:102-8. [PMID: 20011349 DOI: 10.1055/s-2005-870891] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
193 Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005;100:373-82. [PMID: 15667495 DOI: 10.1111/j.1572-0241.2005.40312.x] [Cited by in Crossref: 502] [Cited by in F6Publishing: 510] [Article Influence: 27.9] [Reference Citation Analysis]
194 Si JM, Yu YC, Fan YJ, Chen SJ. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10(12): 1802-1805 [PMID: 15188510 DOI: 10.3748/wjg.v10.i12.1802] [Cited by in CrossRef: 155] [Cited by in F6Publishing: 166] [Article Influence: 8.2] [Reference Citation Analysis]
195 Kurtovic J, Riordan SM. Gut flora and the irritable bowel syndrome. Am J Gastroenterol 2004;99:961-2. [PMID: 15128374 DOI: 10.1111/j.1572-0241.2004.30447.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
196 Pimentel M, Kong Y, Park S. IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. Dig Dis Sci 2004;49:84-7. [PMID: 14992440 DOI: 10.1023/b:ddas.0000011607.24171.c0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
197 Pimentel M, Constantino T, Kong Y, Bajwa M, Rezaei A, Park S. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci 2004;49:73-7. [PMID: 14992438 DOI: 10.1023/b:ddas.0000011605.43979.e1] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
198 Quigley EM. From comic relief to real understanding; how intestinal gas causes symptoms. Gut 2003;52:1659-61. [PMID: 14633937 DOI: 10.1136/gut.52.12.1659] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
199 Pimentel M, Kong Y, Park S. Breath testing to evaluate lactose intolerance in irritable bowel syndrome correlates with lactulose testing and may not reflect true lactose malabsorption. Am J Gastroenterol 2003;98:2700-4. [PMID: 14687820 DOI: 10.1111/j.1572-0241.2003.08670.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 2.8] [Reference Citation Analysis]
200 Talley NJ. Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol 2003;56:362-9. [PMID: 12968980 DOI: 10.1046/j.1365-2125.2003.01966.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 56] [Article Influence: 2.5] [Reference Citation Analysis]
201 Parisi G, Leandro G, Bottona E, Carrara M, Cardin F, Faedo A, Goldin D, Pantalena M, Tafner G, Verdianelli G, Zilli M; AISGE Group. Small intestinal bacterial overgrowth and irritable bowel syndrome. Am J Gastroenterol 2003;98:2572; author reply 2573-4. [PMID: 14638371 DOI: 10.1111/j.1572-0241.2003.08686.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]